| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.9 |